BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/21/2021 9:34:54 AM | Browse: 806 | Download: 1839
 |
Received |
|
2020-12-08 02:59 |
|
Peer-Review Started |
|
2020-12-08 03:00 |
|
First Decision by Editorial Office Director |
|
2021-02-15 00:18 |
|
Return for Revision |
|
2021-02-15 00:18 |
|
Revised |
|
2021-02-21 22:32 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2021-04-06 11:43 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2021-04-14 04:44 |
|
Articles in Press |
|
2021-04-14 04:44 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-04-19 00:40 |
|
Publish the Manuscript Online |
|
2021-04-21 09:34 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Dabigatran, rivaroxaban, and apixaban are superior to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wei-Jia Li, Paraschos Archontakis-Barakakis, Leonidas Palaiodimos, Dimitrios Kalaitzoglou, Lazaros Tzelves, Apostolos Manolopoulos, Yu-Chiang Wang, Stefanos Giannopoulos, Robert Faillace and Damianos G Kokkinidis |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Damianos G Kokkinidis, MD, MSc, Academic Fellow, Doctor, Doctor, Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY 10461, United States. damiankokki@gmail.com |
| Key Words |
Novel oral anticoagulant; Direct oral anticoagulant; Atrial fibrillation; Asian population; Dabigatran; Rivaroxaban; Apixaban; Warfarin |
| Core Tip |
Dabigatran, rivaroxaban, apixaban have better efficacy (reduction in ischemic stroke and all-cause mortality) and are safer (reduction in major bleeding) than warfarin. Dabigatran is associated with a lower rate of intracranial hemorrhage than warfarin, while rivaroxaban and apixaban appear to have a trend towards reduced intracranial hemorrhage, without statistical significance. Dabigatran, rivaroxaban, and apixaban are associated with a lower rate of gastrointestinal bleeding. |
| Publish Date |
2021-04-21 09:34 |
| Citation |
Li WJ, Archontakis-Barakakis P, Palaiodimos L, Kalaitzoglou D, Tzelves L, Manolopoulos A, Wang YC, Giannopoulos S, Faillace R, Kokkinidis DG. Dabigatran, rivaroxaban, and apixaban compared to warfarin in Asian patients with non-valvular atrial fibrillation: An updated meta-analysis. World J Cardiol 2021; 13(4): 82-94
|
| URL |
https://www.wjgnet.com/1949-8462/full/v13/i4/82.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v13.i4.82 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
